• TACTI-004 Phase III trial discontinued following IDMC recommendation
• Root cause analysis ongoing to understand factors behind futility outcome
• Phase I IMP761 data demonstrates favorable safety profile, trial progressing to multiple ascending dose phase
• Cash position of A$110.6 million, providing expected cash reach into H1 CY2028

Immutep Limited, a clinical-stage biotechnology company, provided an update on its activities for the quarter ended 31 March 2026 (Q3 FY26). The key highlights include:LUNG CANCER:- The TACTI-004 Phase III trial evaluating eftilagimod alfa (efti) in first-line non-small cell lung cancer (1L NSCLC) was discontinued following a recommendation from the Independent Data Monitoring Committee (IDMC) based on a planned interim futility analysis. Immutep is conducting a thorough review to understand the factors behind this outcome.SOFT TISSUE SARCOMA: - The investigator-initiated EFTISARC-NEO Phase II trial evaluating efti with radiotherapy plus KEYTRUDA in the neoadjuvant setting for resectable soft tissue sarcoma met its primary objective, showing strong immune system activation.BREAST CANCER:- The AIPAC-003 Phase II trial evaluating efti in combination with chemotherapy in hormone receptor positive (HR+), HER2- negative/low metastatic breast cancer and metastatic triple-negative breast cancer is ongoing, with patients being followed up for overall survival.IMP761 DEVELOPMENT PROGRAM FOR AUTOIMMUNE DISEASE:- The Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody, has completed the single ascending dose portion and is now progressing to the multiple ascending dose phase.FINANCIAL SUMMARY:- Immutep ended the quarter with a cash, cash equivalent, and term deposit balance of approximately A$110.6 million, which is expected to provide a cash reach into H1 CY2028 based on current assumptions. The company is implementing cost reduction measures to preserve capital following the TACTI-004 discontinuation.